RÉSUMÉ
Metronidazole is the drug of choice in the treatment of bacterial vaginosis, but the oral therapy can induce several collateral effects. Aim of this work was the development of a vaginal multiparticulate system, loaded with metronidazole, able to improve its residence time allowing a complete drug release. Several kinds of MS were prepared using chitosan dissolved in different organic acids or alginate coated with chitosan. FTIR and DSC analyses were performed to study the interactions between the drug and the polymers, while MS morphology was investigated with optical and electron microscopy. All the formulations were characterized in terms of drug entrapment efficiency, mucoadhesion, swelling capacity and drug release behavior, demonstrating the best results for alginate MS coated with chitosan. The formulations evidenced a complete and rapid release of drug, compared with the commercial form: Zidoval®.The best formulations assayed for antibacterial activity confirmed the suitability of this new formulation for the vaginal treatment of local diseases.
Sujet(s)
Chitosane , Administration par voie vaginale , Alginates , Femelle , Humains , Métronidazole , MicrosphèresRÉSUMÉ
Nicotine is the specific psychoactive substance of tobacco while tetrahydrocannabinol (THC) is the specific component of cannabis. The inhalation technique of cannabis is different from that of tobacco smoking: the volume of puffs is larger, inhalation is deeper, and pulmonary retention time is longer. Cannabis addiction is difficult to evaluate, both products often being smoked concomitantly. The principle physical side effects of cannabis affect organs and functions in a similar way to tobacco: pulmonary, cardiovascular, endocrine and stomatological. Gastrointestinal complications such as cannabinoid hyperemesis are specific to cannabis. Some psychological effects of THC may be acute (altered time and space perception, sensory disability, decreased vigilance, mood and dissociative disorders, hallucinations and delirium, impaired learning and memory, impaired cognitive and motor performance, panic attacks and anxiety) or chronic (lack of motivation, disorganisation of thoughts, increase in frequency and severity of schizophrenic crises). Cannabis can also be implicated in traffic and workplace accidents. Synthetic cannabinoids have increased psychotropic and somatic effects due to a greater affinity for brain cannabinoid receptors.
Sujet(s)
Cannabis/physiologie , Nicotiana/physiologie , Encéphale/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Cannabinoïdes/pharmacologie , Cannabis/composition chimique , Humains , Abus de marijuana/complications , Abus de marijuana/épidémiologie , Fumer de la marijuana/effets indésirables , Fumer de la marijuana/épidémiologie , Psychoanaleptiques/pharmacologie , Récepteurs de cannabinoïdes/effets des médicaments et des substances chimiques , Récepteurs de cannabinoïdes/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/physiologie , Nicotiana/composition chimique , Fumer du tabac/effets indésirables , Fumer du tabac/épidémiologieRÉSUMÉ
Chitosan-alginate microspheres (MS) were developed for cefixime vaginal administration, to overcome problems associated with its oral administration. The effect of increasing drug-loading amount, by keeping the chitosan-alginate content constant, was investigated. Mucoadhesion studies indicated that all formulations assured in situ permanence longer than 2â¯h. Entrapment efficiency increased with drug loading concentration in the starting solution, reaching a plateau at 30â¯mg/mL indicative of the achievement of an optimal drug-to-polymer ratio. MS swelling properties increased with the entrapped drug amount, and, interestingly, water-uptake reached its maximum value at the same drug loading concentration of 30â¯mg/mL. The relationship found between MS water-uptake and drug release rate confirmed MS prepared with 30â¯mg/mL cefixime as the best formulation. Microbiological studies showed a relation between cefixime release rate from MS and Escherichia coli viability reduction, definitely indicating the selected MS formulation as the best for an effective local treatment of urogenital infections.
Sujet(s)
Alginates/composition chimique , Céfixime/composition chimique , Céfixime/pharmacologie , Chitosane/composition chimique , Vecteurs de médicaments/composition chimique , Microsphères , Adhésivité , Administration par voie vaginale , Anti-infectieux/administration et posologie , Anti-infectieux/composition chimique , Anti-infectieux/pharmacologie , Céfixime/administration et posologie , Libération de médicament , Escherichia coli/effets des médicaments et des substances chimiques , Acide glucuronique/composition chimique , Acides hexuroniques/composition chimique , Muqueuse/composition chimiqueRÉSUMÉ
INTRODUCTION: Healthcare associated infections (HAIs) are a cause of high morbidity, disability and reduced quality of life, as well as mortality and rising costs for health systems. Preventing the HAI risk by planning and implementing effective preventive strategies is important to safeguard patient health. METHODS: The study aimed to evaluate the presence of procedures and protocols for infection control, to assess the adhesion to the different aspects of hand hygiene (HH) and hand washing technique by healthcare workers in six ICUs. A perspective observational study was conducted in six ICUs. In each ICU, the adherence by health care workers to both hand hygiene practices and standard precautions was assessed, as well as the presence of procedures and written protocols. RESULTS: The findings showed that in all the involved ICUs, 73 of 142 required protocols and procedures were available. Specifically, 59 of 79 were available for general measure of risk control, 12 of 15 for hand hygiene, and 24 of 48 for standard precautions and isolation measures. Also, the results showed highly variable levels of adherence to the best hygiene practices in all the ICUs involved in the study, with compliance rates ranging from 3% to 100%, and 73 of 142 required protocols were available at the study time. CONCLUSIONS: Overall, the involved ICUs showed low levels of adherence to best hygiene practices. This suggests the need to implement immediate strategies for infection control in the ICUs. A multidisciplinary intervention could be effective in preventing and control the HAI risk.score was reached only by the third year students with regard to the proper HH. The level of knowledge about HAI was inadequate.A periodically check of nursing students' knowledge would be advisable in order to fill any gaps, improve training, reduce HAI and increase prevention measures compliance.
Sujet(s)
Infection croisée/prévention et contrôle , Adhésion aux directives , Hygiène des mains , Prévention des infections/méthodes , Unités de soins intensifs , Personnel hospitalier , Femelle , Humains , Italie , MâleRÉSUMÉ
BACKGROUND: Bloodstream infections (BSIs) associated with insertion and maintenance of central venous catheters (CRBSIs) are the most frequent causes of healthcare-associated infections in intensive care units (ICUs). They are responsible for increased length of hospital stay and additional healthcare costs. AIM: To investigate whether an educational programme aimed at healthcare workers resulted in a significant change in the level and trend of infections. METHODS: The research was conducted in five Italian ICUs from July 2012 to August 2014. Surveillance and educational interventions to control infections were applied. Compliance with hand hygiene procedures was assessed via relative risk and 95% confidence interval. Interrupted time-series analysis was used to investigate the change in level and trend of infection during the intervention. FINDINGS: Compliance with hand hygiene procedures improved during the intervention for all staff groups, but physicians showed the lowest compliance rates (nurses from 52.4% to 92.1%; nurse aides from 71.0% to 92%; physicians from 71.0% to 92%; P < 0.001). Significant reductions of 21-55% in CRBSI were observed during the intervention. Small improvements in the monthly infection trend were also observed, but these were not statistically significant. CONCLUSION: An educational programme focusing on general good infection control practice, rather than CVC care bundles, led to a decreased CRBSI rate, even if the improvement was not sustained over time. Continuous performance feedback should be provided to promote long-term adherence to guidelines among all health workers.
Sujet(s)
Attitude du personnel soignant , Thérapie comportementale/méthodes , Infections sur cathéters/prévention et contrôle , Cathétérisme veineux central/effets indésirables , Formation médicale continue comme sujet/méthodes , Unités de soins intensifs , Sepsie/prévention et contrôle , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Infections sur cathéters/épidémiologie , Enfant , Enfant d'âge préscolaire , Femelle , Adhésion aux directives , Recherche sur les services de santé , Humains , Nourrisson , Nouveau-né , Prévention des infections/méthodes , Italie , Mâle , Adulte d'âge moyen , Sepsie/épidémiologie , Jeune adulteRÉSUMÉ
The combined strategy of drug-cyclodextrin (CD) complexation and complex loading into nanocarriers (deformable liposomes or nanostructured lipid carriers (NLC)), was exploited to develop effective topical formulations for oxaprozin transdermal administration. Oxaprozin was loaded as ternary complex with randomly-methylated-ßCD and arginine, selected as the best system in improving drug solubility. The colloidal dispersions, characterized for particle size, zeta-potential and entrapment efficiency, were investigated for drug permeation properties in comparison with a plain drug aqueous suspension, a ternary complex aqueous solution and a plain drug liposomal or NLC dispersion. Experiments with artificial membranes showed that the joined use of CD and both liposomes or NLC enabled a marked increase of the drug permeability (16 and 8 times, respectively) and was significantly more effective (P<0.05) than the drug as ternary complex (3.2 times increase), and the corresponding liposomal or NLC dispersion of plain drug (5.6 and 4.3 times increase, respectively). Experiments with excised human skin confirmed the significantly (P<0.05) better performance of deformable liposomes than NLC in promoting drug permeation; moreover, they evidenced a more marked permeability increase compared to the plain drug (24 and 12 fold, respectively), attributed to a possible enhancer effect of the nanocarriers components and/or of the randomly-methylated-ßCD.
Sujet(s)
Cyclodextrines/composition chimique , Vecteurs de médicaments/composition chimique , Lipides/composition chimique , Liposomes/composition chimique , Nanoparticules/composition chimique , Propionates/composition chimique , Administration par voie cutanée , Chimie pharmaceutique/méthodes , Cyclodextrines/administration et posologie , Humains , Nanostructures , Oxaprozine , Taille de particule , Perméabilité/effets des médicaments et des substances chimiques , Propionates/administration et posologie , Peau/métabolisme , Absorption cutanée/effets des médicaments et des substances chimiques , Solubilité , Cyclodextrines bêta/administration et posologie , Cyclodextrines bêta/composition chimiqueRÉSUMÉ
Two kinds of mucoadhesive buccal tablets of clonazepam (CLZ) were developed to provide, a prolonged local or systemic delivery respectively. Tablets prepared by direct compression of combinations of different polymers were tested for swelling, erosion and residence time properties. Carbopol 971P/hydroxypropylmethylcellulose and Poloxamer/chitosan mixtures were the best and were selected for drug loading. The effect of CLZ complexation with different cyclodextrins was investigated. Randomly-methylated-ßCD (RAMEßCD) was the most effective, allowing 100% drug released increase from local-delivery buccal tablets. Kollicoat was the best among the tested backing-layers, assuring a unidirectional release from systemic-delivery buccal tablets (<0.8% drug released in simulated saliva after 24h). In vitro permeation studies from coated-tablets showed that CLZ loading as RAMEßCD-coground enabled a 5-times increase in drug flux and permeability. Therefore, complexation with RAMEßCD was a successful strategy to improve the CLZ performance from buccal tablets for both local or systemic action.
Sujet(s)
Adhésifs , Clonazépam , Cyclodextrines , Adhésifs/composition chimique , Adhésifs/pharmacologie , Administration par voie buccale , Administration par voie topique , Clonazépam/composition chimique , Clonazépam/pharmacocinétique , Clonazépam/pharmacologie , Cyclodextrines/composition chimique , Cyclodextrines/pharmacologie , Humains , ComprimésRÉSUMÉ
A solid lipid nanoparticle (SLN) formulation was developed with the aim of improving the oral bioavailability and the therapeutic effectiveness of glibenclamide (GLI), a poorly water-soluble drug used in the treatment of type 2 diabetes. The SLN was prepared using different lipid components (Precirol® and Compritol®) and preparation procedures. Precirol-based SLN, obtained with the emulsion of solvent evaporation technique gave the best results and was selected for drug loading. Addition of lecithin to the SLN core or PEG coating was effective in increasing the nanoparticles stability in simulated gastric solution. Both such formulations were stable after one month storage at 5±3°C, exhibited the absence of in vitro cytotoxicity, and presented a similar in vitro prolonged-release, reaching 100% release after 24h. The lecithin-containing GLI-loaded SLN formulation, selected for in vivo studies in virtue of its higher EE% than the PEG-coated formulation (70.3% vs 19.6%), showed a significantly stronger hypoglycemic effect with respect to the drug alone, in terms of both shorter onset time and longer duration of the effect. These positive results indicated that the proposed SLN approach was successful in improving GLI oral bioavailability, confirming its potential as an effective delivery system for a suitable therapy of diabetes.
Sujet(s)
Vecteurs de médicaments/composition chimique , Glibenclamide/composition chimique , Glibenclamide/pharmacocinétique , Lipides/composition chimique , Nanoparticules/composition chimique , Administration par voie orale , Animaux , Biodisponibilité , Cellules Caco-2 , Lignée cellulaire tumorale , Chimie pharmaceutique , Diabète de type 2/traitement médicamenteux , Diabète de type 2/métabolisme , Diglycéride/administration et posologie , Diglycéride/composition chimique , Diglycéride/pharmacocinétique , Stabilité de médicament , Émulsions/administration et posologie , Émulsions/composition chimique , Émulsions/pharmacocinétique , Excipients/composition chimique , Glibenclamide/administration et posologie , Humains , Hypoglycémiants/administration et posologie , Hypoglycémiants/synthèse chimique , Hypoglycémiants/pharmacocinétique , Mâle , Nanoparticules/administration et posologie , Rats , Rat Sprague-Dawley , SolubilitéRÉSUMÉ
The aim of this work was to develop a topical formulation with improved permeation properties of acyclovir. Ursodeoxycholic (UDC) and dehydrocholic (DHC) acids were tested as potential enhancers, alone or in combination with different aminoacids. Equimolar binary and ternary systems of acyclovir with cholic acids and basic, hydrophilic or hydrophobic aminoacids were prepared by co-grinding in a high vibrational micromill. Differential scanning calorimetry (DSC) was used to characterize the solid state of these systems, while their permeation properties were evaluated in vitro through a lipophilic artificial membrane. UDC was more than 2 times more effective than DHC in improving drug AUC and permeation rate. As for the ternary systems drug-UDC-aminoacid, only the combined use of l-lysine with UDC acid produced an evident synergistic effect in enhancing drug permeation properties, enabling an almost 3 and 8 times AUC increase compared to the binary UDC system or the pure drug, respectively. The best systems were selected for the development of topical cream formulations, adequately characterized and tested for in vitro drug permeation properties and stability on storage. The better performance revealed by acyclovir-UDC-l-lysine was mainly attributed to the formation of a more permeable activated system induced by the multicomponent co-grinding process.
Sujet(s)
Aciclovir/composition chimique , Acides aminés/composition chimique , Acides et sels biliaires/composition chimique , Calorimétrie différentielle à balayage/méthodes , Chimie pharmaceutique/méthodes , Stabilité de médicament , Stockage de médicament/méthodes , Lysine/composition chimique , Perméabilité , Acide ursodésoxycholique/composition chimiqueRÉSUMÉ
BACKGROUND: Drugs used in obstetric patients must accomplish two goals: efficacy and safety for both mother and fetus. Neostigmine has been co-administered epidurally and intrathecally with local anesthetics and other adjuncts in the obstetric setting. The aim of this meta-analysis was to assess the efficacy and incidence of adverse events related to the use of neostigmine in obstetric anesthesia. METHODS: A meta-analysis of randomized-controlled human trials was conducted using the data sources Google Scholar and PubMed (updated 1 November 2014). Inclusion criteria were: random allocation to treatment; comparison of neostigmine or neostigmine with local anesthetics and/or other adjuvants versus placebo or placebo with local anesthetics and/or other adjuvants; and approval by an ethics committee. RESULTS: The use of neostigmine as an adjuvant in neuraxial anesthesia is associated with a reduction in the dose of local anesthetic during labor analgesia and postoperative analgesia following cesarean section: mean reduction of local anesthetic (ropivacaine or bupivacaine) vs. control -4.08 (95% CI -6.7 to -1.5) mg/h (P=0.002). The risk of nausea was increased vs. control with intrathecal neostigmine (OR 8.99 [95% CI 4.74 to 17.05], P <0.001) but not with epidural neostigmine (OR 0.97 [95% CI 0.46 to 2.05], P=0.94). Use of neuraxial neostigmine was associated with a decrease in the risk of pruritus but there was no increase in the incidence of hypotension, dizziness or sedation and no effect on the incidence of abnormal fetal heart rate patterns or Apgar scores. CONCLUSIONS: Neuraxial administration of neostigmine significantly reduces local anesthetic consumption without serious adverse side effects to the mother or fetus. However, neostigmine is only recommended for epidural administration as intrathecal use significantly increases the incidence of maternal nausea and vomiting.
Sujet(s)
Analgésie obstétricale/méthodes , Anesthésie obstétricale/méthodes , Anesthésiques locaux/administration et posologie , Néostigmine/administration et posologie , Anesthésiques locaux/effets indésirables , Femelle , Humains , Injections rachidiennes , Néostigmine/effets indésirables , GrossesseRÉSUMÉ
The goal of this work was to combine the ketoprofen anti-inflammatory effect with the ascorbic acid antioxidant properties for a more efficient treatment of colonic pathologies. With this aim, microspheres (MS) based on both waxy materials (ceresine, Precirol(®) and Compritol(®)) or hydrophilic biopolymers (pectine, alginate and chitosan) loaded with the two drugs were developed, physicochemically characterized and compared in terms of entrapment efficiency, in vitro release profiles, potential toxicity and drug permeation properties across the Caco-2 cell line. Waxy MS revealed an high encapsulation efficiency of ketoprofen but a not detectable entrapment of ascorbic acid, while polymeric MS showed a good entrapment efficiency of both drugs. All MS need a gastro-resistant coating, to avoid any premature release of the drugs. Ketoprofen release rate from polymeric matrices was clearly higher than from the waxy ones. In contrast, the ASC release rate was higher, due to its high hydro-solubility. Cytotoxicity studies revealed the safety of all the formulations. Transport studies showed that the ketoprofen apparent permeability increased, when formulated with the different MS. In conclusion, only polymeric MS enabled an efficient double encapsulation of both the hydrophilic and lipophilic drugs, and, in addition, presented higher drug release rate and stronger enhancer properties.
Sujet(s)
Anti-inflammatoires non stéroïdiens/administration et posologie , Antioxydants/administration et posologie , Acide ascorbique/administration et posologie , Côlon/métabolisme , Absorption intestinale , Kétoprofène/administration et posologie , Polymères/composition chimique , Cires/composition chimique , Administration par voie orale , Alginates/composition chimique , Anti-inflammatoires non stéroïdiens/composition chimique , Anti-inflammatoires non stéroïdiens/métabolisme , Antioxydants/composition chimique , Antioxydants/métabolisme , Acide ascorbique/composition chimique , Acide ascorbique/métabolisme , Cellules Caco-2 , Chimie pharmaceutique , Chitosane/composition chimique , Diglycéride/composition chimique , Association médicamenteuse , Acide glucuronique/composition chimique , Acides hexuroniques/composition chimique , Humains , Interactions hydrophobes et hydrophiles , Kétoprofène/composition chimique , Kétoprofène/métabolisme , Cinétique , Microsphères , Composés chimiques organiques/composition chimique , Pectine/composition chimique , Perméabilité , Solubilité , Propriétés de surface , Technologie pharmaceutique/méthodesRÉSUMÉ
The occurrence of unprobable adverse events during laparoscopic surgery has increased over the years. Among them, pituitary apoplexy has been reported only twice. The increase in the abdominal pressure might play a role in the pituitary apoplexy, as well as hemodynamic instability, anticoagulant drugs and air-embolism due to insufflation of CO2 during pneumoperitoneum. We report a case of pituitary apoplexy during laparoscopic resection of sigmoid colon.
Sujet(s)
Laparoscopie/effets indésirables , Apoplexie hypophysaire/diagnostic , Apoplexie hypophysaire/étiologie , Complications postopératoires/diagnostic , Complications postopératoires/étiologie , Sujet âgé de 80 ans ou plus , Humains , MâleRÉSUMÉ
A niosomal formulation, functionalized with N-palmitoylglucosamine, was developed as potential brain targeted delivery system of dynorphin-B. In fact, this endogenous neuropeptide, selective agonist of k opioid receptors, is endowed with relevant pharmacological activities on the central nervous system, including a marked antinociceptive effect, but is unable to cross the blood brain barrier (BBB), thus requiring intracerebroventricular administration. Statistical design of experiments was utilized for a systematic evaluation of the influence of variations of the relative amounts of the components of the vesicle membrane (Span 60, cholesterol and SolulanC24) on vesicle mean diameter, polydispersity index and drug entrapment efficiency, chosen as the responses to optimize. A Scheffé simplex-centroid design was used to obtain the coefficients of the postulated mathematical model. The study of the response surface plots revealed that variations of the considered factors had different effects on the selected responses. The desirability function enabled for finding the optimal mixture composition, which represented the best compromise to simultaneously optimize all the three responses. The experimental values obtained with the optimized formulation were very similar to the predicted ones, proving the validity of the proposed regression model. The optimized niosomal formulation of dynorphin-B administered intravenously to mice (100mg/kg) showed a pronounced antinociceptive effect, significantly higher (P<0.05) than that given by i.v. administration of the simple solution of the peptide at the same concentration, proving its effectiveness in enabling the peptide brain delivery. These positive results suggest that the proposed approach could be successfully extended to other neuro-active peptides exerting a strong central action, even at low doses, but unable to cross the BBB.
Sujet(s)
Analgésiques/administration et posologie , Encéphale/effets des médicaments et des substances chimiques , Vecteurs de médicaments/composition chimique , Dynorphines/administration et posologie , Endorphines/administration et posologie , Glycolipides/composition chimique , Analgésiques/pharmacocinétique , Analgésiques/pharmacologie , Analgésiques/usage thérapeutique , Animaux , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Barrière hémato-encéphalique/métabolisme , Encéphale/métabolisme , Préparation de médicament , Systèmes de délivrance de médicaments , Stabilité de médicament , Dynorphines/pharmacocinétique , Dynorphines/pharmacologie , Dynorphines/usage thérapeutique , Endorphines/pharmacocinétique , Endorphines/pharmacologie , Endorphines/usage thérapeutique , Glycolipides/synthèse chimique , Injections veineuses , Injections ventriculaires , Liposomes , Mâle , Souris , Douleur/traitement médicamenteux , Douleur/métabolisme , Récepteur kappa/agonistesRÉSUMÉ
PURPOSE: Thrombocytopenia is a common complication in the intensive care unit (ICU), but the incidence of drug-induced thrombocytopenia (DIT) is not well defined. We investigate linezolid-induced thrombocytopenia in patients with impaired renal function. Since recent studies suggest that linezolid clearance is reduced in these patients and there are no precise data confirming that dose-adjustment should be required, we performed a systematic analysis in order to establish whether it is necessary to consider a dose adjustment and promote studies to confirm this concept. METHODS: We report a case of thrombocytopenia (nadir 32 × 10(3)/µl) in a patient with acute kidney injury who was treated with linezolid for a MRSA pulmonary infection. We performed a systematic review of the literature through PubMed with the aim to include every case report, case series, prospective and retrospective clinical study reporting linezolid-induced thrombocytopenia with concomitant impaired renal function. RESULTS: An increasing number of clinical studies suggest a correlation between the onset of linezolid-induced thrombocytopenia and renal dysfunction. Close monitoring of platelet count and hemoglobin is recommended in patients treated with linezolid, especially in those with impaired renal function because the reduction of its clearance causes drug accumulation, as some studies have reported. CONCLUSIONS: Clinicians should consider the potential risk of this complication, especially in elderly patients with end-stage renal disease. Further studies should be encouraged to determine if the incidence of linezolid-related thrombocytopenia could be reduced by a dose adjustment according to renal function, for which currently there is still no specific recommendation.
Sujet(s)
Acétamides/effets indésirables , Antibactériens/effets indésirables , Oxazolidinones/effets indésirables , Insuffisance rénale/traitement médicamenteux , Thrombopénie/induit chimiquement , Acétamides/administration et posologie , Antibactériens/administration et posologie , Humains , Linézolide , Oxazolidinones/administration et posologieRÉSUMÉ
BACKGROUND: Metformin is known to be rarely associated with lactic acidosis, a serious condition with a poor prognosis. AIM: To review the National Pharmacovigilance Network of the Italian Medicines Agency reporting cases of metformin-associated lactic acidosis. MATERIALS AND METHODS: The National Pharmacovigilance Network of the Italian Medicines Agency, was searched for cases of lactic acidosis that occurred in a 10 years period (from November 2001 to October 2011). Data were analyzed, to identify associated clinical features. A systematic literature research was performed to identify other large case series on metformin associated lactic acidosis. RESULTS: Metformin was the antidiabetic drug most frequently associated with lactic acidosis in the assessed period. Metformin-associated lactic acidosis was the most frequent serious adverse reaction related to metformin reported to the national authority (18.2% of all 650 adverse drug reactions reported). There were 59 cases of metformin-associated lactic acidosis (mortality rate of 25.4%). In most patients (89.8%) there was at least one risk factor for the occurrence of lactic acidosis. The predictors of death were low arterial blood pH and absence of acute renal failure. The systematic research of the literature identified only six case-series with more than 30 patients. CONCLUSIONS: This is the second largest case series ever reported on metformin-associated lactic acidosis. We confirmed that this rare complication of metformin is frequently fatal. Death can be predicted when the patient arrive in the hospital with low pH and, not intuitively, if the patient has no acute kidney injury. Risk minimisation measures taken at national level to prevent this serious complication are described.
Sujet(s)
Acidose lactique/induit chimiquement , Acidose lactique/thérapie , Hospitalisation , Hypoglycémiants/effets indésirables , Metformine/effets indésirables , Acidose lactique/diagnostic , Acidose lactique/mortalité , Systèmes de signalement des effets indésirables des médicaments , Sujet âgé , Femelle , Enquêtes de santé , Humains , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Pronostic , Facteurs de risque , Facteurs tempsRÉSUMÉ
In France, workplace testing of drugs of abuse and psychotropic drugs is rarely performed; meanwhile it is a major public health problem. Furthermore, France is the European country that has been associated with the highest increase of the use of drugs of abuse, particularly cannabis. So workplace biological screening of drugs of abuse and of psychotropic drugs exposure is of major concern. New analytical techniques have been developed during the last years. The authors will consider analytical screening of drugs of abuse and particularly the comparison of analytical techniques applied to urine and saliva. The advantages and the disadvantages of these two matrices will be considered. Urinary and blood quantification will be reviewed, but also the interest of hair testing to explore chronic exposure. The research of psychotropic drugs in biological fluids is also a part of this paper. New analytical trends are promising and complete analysis of these substances will be soon routinely possible in blood using a single spot test.
Sujet(s)
Substances illicites/analyse , Psychoanaleptiques/analyse , Détection d'abus de substances/méthodes , Lieu de travail , Troubles liés aux amphétamines/diagnostic , Cannabinoïdes/analyse , Maladie chronique , Troubles liés à la cocaïne/diagnostic , Dronabinol/analyse , Faux négatifs , Faux positifs , France , Humains , Substances illicites/urine , Troubles liés aux opiacés/diagnostic , Reproductibilité des résultats , Salive/composition chimique , Troubles liés à une substance/diagnosticRÉSUMÉ
A new delivery system based on drug cyclodextrin (Cd) complexation and loading into nanostructured lipid carriers (NLC) has been developed to improve ketoprofen therapeutic efficacy. The proposed strategy exploits both the solubilizing and stabilizing properties of Cds and the prolonged release, high tolerability and percutaneous absorption enhancer properties of NLC. Two different polymeric Cds, i.e. ß-Cd-epichlorohydrin polymer (EPI-ßCd) and carboxymethylathed-ß-Cd-epichlorohydrin polymer (EPI-CMßCd) were tested and two different techniques to obtain solid ketoprofen-polymeric Cd complexes (i.e. co-grinding and co-lyophilization) were compared, to investigate the influence of the preparation method on the physicochemical properties of the end product. EPI-ßCd was more effective than EPI-CMßCd in enhancing the solubility and dissolution properties of ketoprofen. Co-grinding in dry conditions was the best preparation technique of solid drug-Cd systems, allowing obtainment of homogeneous amorphous particles of nanometric range. NLC consisting in a mixture of Compritol® 888 ATO (glyceryl behenate) and Labrafac Lipophile were obtained by ultrasonication. Both empty and loaded NLC were suitably characterized for particle size, pH, entrapment efficiency and drug release behavior. The best (drug-Cd)-loaded NLC system, formulated into a xanthan hydrogel, exhibited drug permeation properties clearly better than those of the plain drug suspension or the plain drug-loaded NLC, in virtue of the simultaneous exploitation of the solubilizing effect of cyclodextrin and the penetration enhancer properties of NLC.
Sujet(s)
Cyclodextrines/composition chimique , Vecteurs de médicaments/composition chimique , Épichlorohydrine/composition chimique , Kétoprofène/administration et posologie , Kétoprofène/composition chimique , Lipides/composition chimique , Nanostructures/composition chimique , Polymères/composition chimique , Cyclodextrines bêta/composition chimique , Administration par voie topique , Chimie pharmaceutique/méthodes , Cyclodextrines/administration et posologie , Préparations à action retardée/administration et posologie , Préparations à action retardée/composition chimique , Vecteurs de médicaments/administration et posologie , Stabilité de médicament , Épichlorohydrine/administration et posologie , Lyophilisation/méthodes , /administration et posologie , /composition chimique , Lipides/administration et posologie , Nanostructures/administration et posologie , Taille de particule , Perméabilité , Polymères/administration et posologie , Polyosides bactériens/administration et posologie , Polyosides bactériens/composition chimique , Solubilité , Cyclodextrines bêta/administration et posologieRÉSUMÉ
The aim of the present work was to develop a new multiparticulate system, designed for colon-specific delivery of celecoxib for both systemic (in chronotherapic treatment of arthritis) and local (in prophylaxis of colon carcinogenesis) therapy. The system simultaneously benefits from ternary complexation with hydroxypropyl-ß-cyclodextrin and PVP (polyvinylpyrrolidone), to increase drug solubility, and vectorization in chitosan-Ca-alginate microspheres, to exploit the colon-specific carrier properties of these polymers. Statistical experimental design was employed to investigate the combined effect of four formulation variables, i.e., % of alginate, CaCl2, and chitosan and time of cross-linking on microsphere entrapment efficiency (EE%) and drug amount released after 4h in colonic medium, considered as the responses to be optimized. Design of experiment was used in the context of Quality by Design, which requires a multivariate approach for understanding the multifactorial relationships among formulation parameters. Doehlert design allowed for defining a design space, which revealed that variations of the considered factors had in most cases an opposite influence on the responses. Desirability function was used to attain simultaneous optimization of both responses. The desired goals were achieved for both systemic and local use of celecoxib. Experimental values obtained from the optimized formulations were in both cases very close to the predicted values, thus confirming the validity of the generated mathematical model. These results demonstrated the effectiveness of the proposed jointed use of drug cyclodextrin complexation and chitosan-Ca-alginate microsphere vectorization, as well as the usefulness of the multivariate approach for the preparation of colon-targeted celecoxib microspheres with optimized properties.
Sujet(s)
Alginates/composition chimique , Calcium/composition chimique , Chitosane/composition chimique , Côlon/métabolisme , Microsphères , Pyrazoles/composition chimique , Sulfonamides/composition chimique , Cyclodextrines bêta/composition chimique , 2-Hydroxypropyl-beta-cyclodextrin , Alginates/administration et posologie , Calcium/administration et posologie , Célécoxib , Chimie pharmaceutique/méthodes , Chitosane/administration et posologie , Systèmes de délivrance de médicaments/méthodes , Acide glucuronique/administration et posologie , Acide glucuronique/composition chimique , Acides hexuroniques/administration et posologie , Acides hexuroniques/composition chimique , Taille de particule , Polymères/administration et posologie , Polymères/composition chimique , Povidone/administration et posologie , Povidone/composition chimique , Pyrazoles/administration et posologie , Solubilité , Sulfonamides/administration et posologie , Cyclodextrines bêta/administration et posologieRÉSUMÉ
Pectinate-chitosan-beads aimed for colon theophylline delivery have been developed. The effect of zinc or calcium ions as cross-linking agent, and of chitosan concentration on the properties and colon-targeting performance of beads was investigated. Beads were characterized for morphology, entrapment efficiency and mucoadhesion properties. Zn-pectinate-chitosan beads formed a stronger gel network than the Ca-containing ones, enabling a greater entrapment efficiency, which further increased with chitosan content, probably due to polyelectrolyte complexes formation. Transport studies across Caco-2 cells evidenced a significant (p > 0.05) drug permeation increase from all beads with respect to drug alone, attributable to the enhancer and/or mucoadhesion properties of the polymers, and Ca-pectinate-chitosan beads were more effective than the Zn-containing ones. Beads formulated as enteric-coated tablets demonstrated good colon-targeting properties, and no differences were observed in drug-release profiles from Zn- or Ca-pectinate-chitosan beads. Therefore, Ca-pectinate-chitosan beads emerged as the choice formulation, joining colon-targeting specificity with better permeation enhancer power.
Sujet(s)
Chitosane/composition chimique , Côlon/métabolisme , Réactifs réticulants/composition chimique , Systèmes de délivrance de médicaments , Excipients/composition chimique , Muqueuse intestinale/métabolisme , Pectine/composition chimique , Adhésivité , Cellules Caco-2 , Calcium/administration et posologie , Calcium/composition chimique , Calcium/métabolisme , Perméabilité des membranes cellulaires , Phénomènes chimiques , Chimie pharmaceutique , Agents gastro-intestinaux/administration et posologie , Agents gastro-intestinaux/composition chimique , Agents gastro-intestinaux/métabolisme , Humains , Absorption intestinale , Microsphères , Solubilité , Théophylline/administration et posologie , Théophylline/composition chimique , Théophylline/métabolisme , Zinc/administration et posologie , Zinc/composition chimique , Zinc/métabolismeRÉSUMÉ
The effect of the combined use of randomly methylated ß-cyclodextrin (RAMEB), chitosan (CS), and bile components (dehydrocholic (DHCA) or ursodeoxycholic (UDCA) acids and their sodium salts) on solubility and permeability through Caco-2 cells of oxaprozin (a very poorly water-soluble non-steroidal anti-inflammatory drug) has been investigated. Addition of CS, bile acids, and their sodium salts increased the RAMEB solubilizing power of 4, 2, and 5 times, respectively. Drug-RAMEB-CS co-ground systems showed very higher dissolution rate than corresponding drug-RAMEB systems. Addition of bile components further improved drug dissolution rate. The CS presence enabled a significant increase in drug permeability through Caco-2 cells with respect to drug-RAMEB systems. Moreover, CS and NaDHC showed a synergistic enhancer effect, enabling a 1.4-fold permeability increase in comparison with systems without bile salt. However, unexpectedly, no significant differences were found between physical mixtures and co-ground products, indicating that drug permeation improvement was due to the intrinsic enhancer effect of the carriers and not to drug-carrier interactions brought about by co-grinding, as instead found in dissolution rate studies. The combined use of RAMEB, CS, and NaDHC could be exploited to develop effective oral dosage forms of oxaprozin, with increased drug solubility and permeability, and then improved bioavailability.